<DOC>
	<DOCNO>NCT00751504</DOCNO>
	<brief_summary>Atypical antipsychotic find beneficial treatment psychotic disorder , even depressive symptom patient schizophrenia . Remarkably , preliminary data suggest atypical antipsychotic quetiapine antidepressive property . Until , limit knowledge concern efficacy quetiapine major depressive illness especially psychotic depression . In clinical practice , several patient psychotic depression successfully treated quetiapine add-on therapy monotherapy . On background , convince effect quetiapine bipolar depression , single-case report pilot study concern effectiveness depressive mood state psychotic disorder well clinical experience , assume treatment quetiapine 6 week period show similar effect major depressive episode psychotic feature , i.e . psychotic depression . In pilot study plan investigate 20 patient psychotic feature depression treatment quetiapine .</brief_summary>
	<brief_title>Quetiapine Treatment Psychotic Depression - Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>provision write informed consent diagnosis depression psychotic feature DSMIV ( 296.23 , 296.33 ) female male age 18 65 year female patient childbearing potential must use reliable method contraception negative pregnancy test enrollment patient must able understand comply requirement study MADRS score 20 point pregnancy lactation DSMIV Axis I disorder define inclusion criterion full remission patient , opinion investigator , pose imminent risk suicide danger self others know intolerance lack response quetiapine , judge investigator use cytochrome P450 3A4 inhibitor 14 day precede enrollment use cytochrome P450 inducer 14 day precede enrollment thyroidstimulating hormone ( TSH ) concentration 10 % upper limit normal range enrollment administration depot antipsychotic injection within one dose interval randomisation substance alcohol dependence enrollment , define DSMIV opiate , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrollment medical condition would affect absorption , distribution , metabolism , excretion study treatment risk transmit human immunodeficiency virus ( HIV ) hepatitis B via blood body fluid unstable inadequately treat medical illness , judge investigator patient diabetes mellitus ( DM ) absolute neutrophil count ( ANC ) &lt; 1.5x10E9 per liter history idiopathic orthostatic hypotension , condition would predispose ECG consider show clinically significant abnormality enrollment determine cardiologist involvement plan conduct study previous enrollment randomisation treatment present study serious unstable somatic illness , opinion investigator , would negatively affect study medication participation another drug trial within 4 week prior enrollment study patient unsufficient knowledge German language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Quetiapine</keyword>
	<keyword>Psychotic depression</keyword>
</DOC>